Janus Henderson Concentrated All Cap Growth Managed Account Q1 2025 Commentary
Source: SeekingAlpha
2025-05-20 00:44:00 ET
Summary
- Concentrated All Cap Growth Managed Account returned -9.25% (gross) and the Russell 3000® Growth Index returned -10.05%.
- Stock selection in the consumer discretionary and financials sectors contributed to relative performance, while selection in information technology and healthcare detracted.
- Despite significant near-term volatility, we continue to focus on competitively advantaged companies positioning themselves for market share gains when conditions stabilize.
Performance - USD (%)
| Cumulative | Annualized | ||||||
| Returns | 1Q25 | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Since inception (01/01/05) |
| Composite (pure gross*) | -9.25 | -9.25 | 3.54 | 7.59 | 16.11 | 13.77 | 13.03 |
| Composite (Net) | -9.95 | -9.95 | 0.52 | 4.46 | 12.75 | 10.48 | 9.76 |
| Russell 3000 ® Growth Index | -10.05 | -10.05 | 7.12 | 9.61 | 19.56 | 14.54 | 11.55 |
Read the full article on Seeking Alpha
For further details see:
Janus Henderson Concentrated All Cap Growth Managed Account Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-4.98% G/L:
$56.52 Last:
259,831 Volume:
$58.62 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
